Trulicity is the brand name for a molecule used in the treatment of type 2 diabetes. The generic name is Dulaglutide. It is a relatively new product and is a type of injectable therapy, but it is not insulin. It comes in the form of a disposable single use pen in either 0.75mg dose and 1.5mg dose, making it relatively safe and easy to administer.
Trulicity (dulaglutide) is not insulin but is a different type of diabetes medicine called a GLP-1 analogue. It is a small protein just like insulin (called a peptide) and because proteins are easily broken down by stomach acids, which would make the protein inactive, both insulin and Trulicity (dulaglutide) need to be injected under the skin. This allow the molecule to get into the body but bypasses the gut.
Trulicity is available in either 0.75mg or 1.5mg pens. Generally people should be started on the lower dose and increased after 3 to 6 months. This reduces the side effects substantially. In many countries only 1.5mg is available.
In the Award 11 Study 1,842 adults with type 2 diabetes were given 1.5mg, 3mg or 4.5mg weekly doses. Those taken the high dose had a greater reduction in Hb A1c (1.53% for the 1.5 mg dose, 1.71% for the 3 mg dose and 1.87% for the 4.5 mg dose. The higher the dose of Trulicity the greater the weight loss with the highest 4.5mg dose associated with about 4.7kg weight loss. The increased doses are now FDA approved in the United States
Trulicity is administered once a week as injection under the skin.
To help remember what day to take your Trulicity, it is useful to have a reminder in your phone each week. It does not matter what day of the week to administer Trulicity (Dulaglutide) so it is best to choose a day that best fits a person's lifestyle. For example, you might choose Sunday as your day to administer Trulicity. You can place a recurring alarm in your phone, so you don't forget. You administer it once every Sunday and that's done. Pretty simple!
Yes. Trulicity can cause weight loss, although it is not a weight loss drug.
There have been a number of studies examining the effectiveness of Trulicity (Dulaglutide) in managing type 2 diabetes. These studies, the AWARD studies, also looked at the associated weight loss in patients using Trulicity. In one of the AWARD studies Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5), it showed that Trulicity was more effective in causing weight loss compared to another type 2 diabetes medication, called sitagliptin (a DPP-4 inhibitor). The average change in body weight was 2.6kg (with the 0.75mg weekly dose of Trulicity) and 3kg (with the 1.5mg weekly dose of Trulicity). This is compared to a 1.53kg weight loss with patients who used sitagliptin.
The Sustain 7 study compared the treatment outcomes of Ozempic with Trulicity. Both of these drugs are once weekly GLP-1 analogues used in the treatment of type 2 diabetes.
Ozempic compared to Trulicity led to:
The AWARD-6 study looked at comparing once weekly Trulicity with once daily Victoza (Liraglutide). The results of this study in people with type 2 diabetes suggests that they are similar in terms of Hb A1c reduction. There was slightly more weight loss with Victoza. Nausea rates were similar with both drugs.
The following drugs are all based on the GLP-1 or Exendine molecule:Administered weekly
Did you know that GLP-1 has many effects in the body?
As we’ve discussed above, GLP-1 is a hormone that is released from our small intestines in response to food. When GLP-1 is released, it binds to specific GLP-1 receptors. These receptors can be found in various areas of the body (GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody), including in the:
Please see the following articles for more information:
For more information about different Diabetes Treatments, please follow the links below.